
Ocular Therapeutix Stock Plunge Today: What Is This Company and Why Does Wet AMD Drug AXPAXLI Matter?
AXPAXLI, a long-acting wet macular degeneration therapy, explained by a Seoul ophthalmologist
Quick Answer
Ocular Therapeutix (NASDAQ: OCUL) is a US ophthalmology biotech whose value rests largely on AXPAXLI™, a long-acting axitinib hydrogel for wet age-related macular degeneration (wet AMD). The company recently completed a Pre-NDA meeting with the FDA and plans an NDA submission in Q4 2026. A drop in the share price is not proof that the drug has failed, and wet AMD patients in Seoul, including Guro and Gasan, should not wait for it: it is not yet approved.
Hello. I am Dr. Daniel Baik, board-certified ophthalmologist and director of Nunehim Eye Center on Siheung-daero in Guro-gu, Seoul, near Gasan Digital Complex and Guro Digital Complex, and convenient from Yeongdeungpo and Gwanak.
If you followed the US market today, you may have seen a lesser-known biotech move sharply: Ocular Therapeutix, ticker OCUL. As an ophthalmologist, I find the drug the company is developing far more interesting than the share price. That drug is AXPAXLI™, a next-generation, long-acting treatment for wet age-related macular degeneration (wet AMD), a disease I manage in the clinic. This is not investment advice; it is an ophthalmologist’s explanation of what the company does and why the market is so sensitive to it.
Q. Why is Ocular Therapeutix getting so much attention today?
Ocular Therapeutix is not a large pharmaceutical company selling drugs across many fields. Much of its value depends on whether AXPAXLI succeeds, so small changes can move the stock sharply: trial results, FDA discussions, the filing timeline, additional clinical data, safety, financing and competing therapies.
The company’s latest key news is actually positive. It has completed a Pre-NDA meeting with the FDA and is pursuing a New Drug Application (NDA) in Q4 2026. I could not identify a single, clear trigger for today’s drop or its exact size from currently available public data. The most recent closes I could find were $9.65 on September 25 (−1.73%), after −4.76% on September 23 and −1.80% on September 24, so the shares had been weak for several days. Reading a short-term drop as “the drug failed” is premature. Biotech shares also move on expectations, financing, risk appetite across the market and the perceived odds of approval.
Q. What does Ocular Therapeutix develop?
The core of the company is a drug delivery system for long-lasting retinal treatment. Its lead candidate is AXPAXLI (formerly OTX-TKI), which combines two technologies.
First, axitinib. Axitinib is a tyrosine kinase inhibitor (TKI) that acts on the VEGF receptor and suppresses the signal that drives abnormal blood vessel growth, the central process in wet AMD.
Second, a hydrogel delivery system. The real distinction is the delivery method: axitinib is placed in a bioresorbable hydrogel injected into the vitreous cavity, designed to release drug slowly. In other words, one injection that releases medicine gradually over a long time. The company is developing AXPAXLI to control disease with roughly one to two doses a year.
Q. What is wet AMD?
At the back of the eye is the retina, like the film in a camera. At its center is the macula, which provides fine central vision: reading, recognizing faces, driving and seeing small objects. Age-related macular degeneration comes in two forms, dry and wet. In wet AMD, abnormal, fragile new vessels grow beneath the macula and leak fluid and blood, causing subretinal or intraretinal fluid, macular edema, hemorrhage and pigment epithelial detachment. Over time, fibrosis and atrophy can permanently damage central vision.
Symptoms that warrant a macular exam
Patients often say:
- “The door frame looks bent.”
- “The middle of the letters is missing.”
- “The center of people’s faces looks blurry.”
- A sudden drop in vision in one eye
These are typical of metamorphopsia and central scotoma. Once photoreceptors are badly damaged and scarred, controlling the vessels afterwards may not restore the lost vision, so early detection plus continuous treatment matters most.

Q. How is wet AMD treated today?
The current standard is intravitreal anti-VEGF injection with drugs such as aflibercept, ranibizumab and faricimab, which stop new vessels from leaking fluid and blood. The catch is that repeat treatment may be needed to keep the effect. Newer drugs such as Eylea HD and Vabysmo allow considerably longer intervals, but many patients still need regular OCT checks and repeated injections.
This is why AXPAXLI matters. Its goal is simple: how long can VEGF signaling be suppressed after a single treatment? Conventional treatment produces a peak drug level that then falls. If axitinib is released steadily from a hydrogel, VEGF suppression could be more constant, shifting care from “inject after the disease reactivates” toward “keep it from reactivating.”
AXPAXLI vs. current anti-VEGF therapy
| Current anti-VEGF | AXPAXLI | |
|---|---|---|
| Mechanism | VEGF inhibition | VEGF receptor inhibition via axitinib (TKI) |
| Delivery | Intravitreal injection | Intravitreal hydrogel implant |
| Duration | Weeks to months, by drug and patient | Long-term release is the goal |
| Strength | Extensive efficacy and safety data | Potentially fewer injections |
| Limitation | Repeated visits and injections | Not yet approved |
| Stage | Standard of care | Late-stage; US NDA in preparation |
Q. How did AXPAXLI do in clinical trials?
One of the most important studies is the SOL-1 Phase 3 trial, in which AXPAXLI met its primary endpoint. So this is not an early-stage idea but a therapy that has reached late-stage development aimed at approval. Ocular Therapeutix is reorganizing its retina business around AXPAXLI and is also developing it for diabetic retinopathy. Public company descriptions currently list it as an axitinib intravitreal hydrogel in Phase 3 for wet AMD and non-proliferative diabetic retinopathy.
Why do shares of such a company swing so much in a day? Its value depends more on the future drug than on current revenue. Higher odds of FDA approval can lift the stock sharply, while delays, extra trial requirements, financing needs, share issuance (dilution) or strong competitor data can push it down even if the drug itself is fine. Regulatory execution, rising costs and dilution risk are among the points investors are told to watch. A falling price does not mean the drug failed, and a rising price does not mean it worked. To an ophthalmologist, what matters is clinical data and how long and how safely the effect lasts in real patients.

1. FDA NDA submission
The company plans an NDA in Q4 2026.
2. Actual approval
A successful Phase 3 is not approval. The FDA weighs efficacy, safety, manufacturing and repeat-dosing data.
3. Real duration and repeat safety
Can it become a once- or twice-yearly therapy? Wet AMD is treated for years, so long-term safety after repeated dosing is key.
A word from Dr. Daniel Baik
“What interests me more than this price move is the shift in retinal treatment behind it. The goal used to be a good anti-VEGF drug; the new competition is how long the effect can be kept stable. High-dose anti-VEGF, bispecific antibodies, implants, TKIs and gene therapy are all being studied. But more important than any new drug is finding macular degeneration early: if lines look bent, letters go missing or one eye’s center is blurry, do not blame presbyopia. Get a fundus exam and OCT.”

❓ Frequently Asked Questions
Q. Ocular Therapeutix fell today. Did AXPAXLI fail?
Nothing in the company announcements I can verify supports that. After the recent FDA Pre-NDA meeting the company is maintaining its plan for an NDA in Q4 2026. Biotech shares can still swing on regulatory timing, financing and market expectations.
Q. Can wet AMD patients get AXPAXLI now?
No. It is not yet approved by the US FDA.
Q. If approved, will one injection a year be enough?
Not yet known. The company is targeting one to two doses a year, but the approved regimen and each patient’s interval depend on future data and the FDA label.
Q. Should current AMD patients wait for AXPAXLI?
No. Delaying wet AMD treatment can cause irreversible damage to the macula, so receive proven treatment on time.
Q. Where can I get a macular exam near Guro, Gasan, Yeongdeungpo or Gwanak?
Nunehim Eye Center in Guro-gu offers a fundus exam and OCT in English and Korean, easily reached from Guro, Gasan, Yeongdeungpo and Gwanak.
In one line: Ocular Therapeutix’s core asset AXPAXLI is a next-generation, long-acting wet AMD therapy that releases axitinib over a long time to reduce repeated eye injections; what matters next is FDA approval, real duration and repeat-dosing safety. This article is general information, not investment advice or individual medical advice.



Book a Consultation
Worried about macular degeneration or retinal disease near Guro, Gasan, Yeongdeungpo or Gwanak? Book a detailed retinal exam.
📍 Visit Nunehim Eye Center — Guro, Seoul
We are on Siheung-daero in Guro-gu, easy to reach from Gasan, Gwanak, Yeongdeungpo and Guro Digital Complex. Consultations in Korean and English.
Address
551 Siheung-daero, Guro-gu, Seoul
nunehim.com
Hours
Mon–Fri 09:00–18:30
Lunch 13:00–14:00
Sat 09:00–14:00
Languages
Korean & English
Leave a Reply